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correlated strongly: 0.75 (p < 0.001). The responsiveness was
moderate for SF-6D (SRM = 0.40) and high for EQ-5D
(SRM = 0.83). CONCLUSION: Both SF-6D and EQ-5D cap-
tured worsening and improvements in health over time.
However, the use of EQ-5D resulted in larger utility losses and
gains and in consequence may result in lower cost-utility ratios.
The study showed high responsiveness for EQ-5D and moderate
for SF-6D, indicating that EQ-5D is more suitable for use as
utility measure in clinical trials in elderly hip fracture patients.
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OBJECTIVES: To determine whether sub-acute lack of asthma
control (SALAC), independent of current exacerbations, is asso-
ciated with subsequent acute asthma exacerbations. METHODS:
Patients who were aged 12 years as of 2001, continuously
enrolled throughout 2001–2004, and had 1 claims for asthma
(ICD-9-CM code 493.x), no claims for COPD or cystic ﬁbrosis,
and 1 prescriptions for an asthma medication anytime during
2001–2004 were identiﬁed using administrative claims data from
PharMetrics/IMS Health. SALAC was deﬁned as >4 physician
visits for asthma per year (or 2 per quarter) or >5 SABA
prescriptions per year. The impact of asthma control category
during 2001 (exacerbation only, SALAC only, both exacerbation
and SALAC, or neither exacerbation nor SALAC) on having 1
acute asthma exacerbations (hospital admissions, ED visits, or
short-term courses of oral corticosteroid therapy within 7 days of
a physician ofﬁce visit) anytime during 2002–2004 was assessed
using logistic regression. Covariates included gender, age, insur-
ance type, and region. RESULTS: Among 11,779 asthma patients
in 2001, 8% experienced an exacerbation only (EO), 26% expe-
rienced SALAC only (SO), 12% had both an exacerbation and
SALAC (Both), and 54% had neither an exacerbation nor
SALAC (Neither). The 2002–2004 exacerbation rate was higher
in the Both group vs. the EO group (61.8% vs. 55.0%) and in the
SO group vs. the Neither group (37.3% vs. 31.9%). Controlling
for the covariates and compared with the Neither group, the
Both group had a larger impact on the odds of an exacerbation
in 2002–2004 than did the EO group (3.394 [95% CI: 3.009,
3.827] vs. 2.503 [2.176, 2.879], and the SO group had a signiﬁ-
cant and positive effect (1.277 [1.166, 1.399]). CONCLUSION:
SALAC identiﬁes an additional 26% of asthma patients who
have a higher likelihood of a subsequent exacerbation in addition
to the 20% who experienced an exacerbation in 2001.
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OBJECTIVES: Severe persistent asthma is not always adequately
controlled and its prevalence is unknown among pneumology
and allergy hospital units. The aim of this study is to determine
uncontrolled severe persistent asthma prevalence among asth-
matic patients attended in hospital units, to describe their clinical
characteristics and to determine the prevalence of sensibility to
common aeroallergens. METHODS: Cross-sectional epidemio-
logic study conducted in 201 hospital pneumology and allergol-
ogy units in Spain. Asthmatic patients attending these services (in
and out-patients) during a 6-month period were registered.
Demographic data, clinical characteristics, skin-prick test, total
serum IgE, asthma control test (ACQ) and quality of life (AQLQ)
assessments were collected among a sample of asthmatics
patients. RESULTS: A total of 1,423 (3.9% [CI 95%: 3.7–
4.1%]) out of 36,649 asthma patients attending hospital units,
had uncontrolled severe disease, data from 330 was collected.
They showed a poor asthma control (a mean (SD) ACQ score
4.17 [0.96]). 55.9% of the sample had a positive skin-prick test
to common aeroallergens and 53.6% showed high levels of total
serum IgE. The percentage agreement between control assess-
ment by the investigator and by GINA guidelines was moderate
(65.3%, Kappa = 0.365), this discrepancy is basically explained
by an overestimation of control by specialists. CONCLUSION:
1) Uncontrolled severe persistent asthma shows a limited preva-
lence among hospital asthma patients in Spain; 2) The level of the
asthma control is overestimated by physicians; and 3) A half of
the sample fulﬁlled criteria of the allergic disease.
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OBJECTIVES: A budget impact model was developed to esti-
mate the economic impact of introducing beclomethasone/
formoterol extraﬁne for the treatment of moderate to severe
persistent asthma in Spain. METHODS: The analytic model is
based on data from disease prevalence, population growth, drug
consumption, ex-factory prices and market shares forecasting
for Spain. It takes the perspective of the Spanish National Phar-
maceutical budget and time horizon considered is 5 years.
Annual discount rate was set at 5%. Drugs considered in the
study were ﬂuticasone/salmeterol, budesonide/formoterol and
beclomethasone/formoterol extraﬁne. The model estimates the
annual cost to treat patients with moderate to severe persistent
asthma before and after the introduction of beclomethasone/
formoterol extraﬁne in Spain. Annual costs consist of pharma-
cologic treatment costs, laboratory and diagnostic tests costs,
specialist consultation costs and hospitalization costs. All costs
are referred to 2007. RESULTS: It has been estimated that target
population with moderate to severe persistent asthma in Spain
would be around 284,365 in year 2007, arriving at 498,385 in
2012 due to increase in Spanish population and the increase of
asthma prevalence. Total cost for the next 5 years for the treat-
ment of moderate to severe persistent asthma in Spain was
estimated at 1700€ millions before the introduction of
beclomethasone/formoterol extraﬁne and at 1689€ millions after
its introduction. Mean cost per patient was estimated at 642€
before the introduction of beclomethasone/formoterol extraﬁne
and at 637€ after its introduction. CONCLUSION: This budget
impact model estimates that the introduction of beclomethasone/
formoterol extraﬁne for the treatment of moderate to severe
A398 Abstracts
